Exenatide: all 231 studies that test it

Page 1 of 3. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.

• Exenatide Pharmacokinetics and Pharmacodynamics in Gestational DiabetesRecruitingNCT05482789Phase 4
• Pharmacogenomics of GLP1 Receptor AgonistsTerminatedNCT05762744Phase 1Results posted
• Exenatide for Treating Cocaine Use DisorderCompletedNCT04941521Phase 1/2Results posted
• Exenatide Once-weekly as a Treatment for Multiple System AtrophyCompletedNCT04431713Phase 2Results posted
• Assess the Efficacy and Safety of Exenatide SR for the Prevention of Diabetes After Kidney TransplantationCompletedNCT03961256Phase 2Results posted
• The Effects of Exenatide, a GLP-1 Agonist, on Alcohol Self-Administration in Heavy DrinkersTerminatedNCT03645408Phase 1Results posted
• Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in GlucosuriaCompletedNCT03331289Phase 4Results posted
• Bexagliflozin Drug/Drug Interaction Study With Exenatide InjectionCompletedNCT03167411Phase 1Results posted
• GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 DiabetesTerminatedNCT03029351Phase 4Results posted
• Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DMCompletedNCT02981069Phase 4Results posted
• Exenatide Once Weekly for Smoking CessationCompletedNCT02975297Phase 1/2Results posted
• An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 DiabetesCompletedNCT02962492Not applicableResults posted
• An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus SubjectsTerminatedNCT02793154Phase 4Results posted
• Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic ObesityCompletedNCT02664441Phase 3Results posted
• A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients.CompletedNCT02533453Phase 4Results posted
• Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 DiabetesCompletedNCT02455076Phase 4Results posted
• Exenatide Weekly Injections as an Adjunctive Treatment in Patients With SchizophreniaCompletedNCT02417142Phase 4Results posted
• Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes.CompletedNCT02288273Phase 4Results posted
• Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal SyndromeCompletedNCT02251431Phase 3Results posted
• Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes MellitusCompletedNCT02229383Phase 3Results posted
• Effect of Exenatide in Obese Patients With Accelerated Gastric EmptyingCompletedNCT02160990Phase 4Results posted
• Liver and Fat Regulation in Overweight Adolescent GirlsCompletedNCT02157974Phase 2/3Results posted
• A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 DiabetesCompletedNCT02119819Phase 2Results posted
• Effects of Antidiabetic Medications on the Postprandial State in PrediabetesCompletedNCT02104739Phase 4Results posted
• Intravenous Exenatide in Patients With Acute Brain InjuryCompletedNCT02058940Phase 4Results posted
• A Study of the Safety and Effectiveness of LY3053102 in Participants With Type 2 DiabetesTerminatedNCT02020616Phase 1/2Results posted
• Effect of Exenatide on Liver and Heart Fat and InflammationCompletedNCT01951651Phase 4Results posted
• A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I DiabetesCompletedNCT01928329Phase 2Results posted
• Open Label, 4 Week Study of ITCA 650 in Adults With Type 2 DiabetesCompletedNCT01798264Phase 1Results posted
• Pilot Study of Bydureon to Treat Diabetes in HIV-infected AdultsTerminatedNCT01791465Phase 4Results posted
• Weight Loss With Exenatide TreatmentCompletedNCT01590433Phase 4Results posted
• Acute Effect of Exenatide on Brain Glucose MetabolismCompletedNCT01588418Phase 4Results posted
• Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 DiabetesCompletedNCT01554618Phase 3Results posted
• FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)CompletedNCT01524705Phase 4Results posted
• Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain TumorCompletedNCT01484873Phase 2Results posted
• Effects of Exenatide on Overweight Adolescents With Prader-Willi SyndromeCompletedNCT01444898Not applicableResults posted
• Effect Of Exenatide Treatment on Liver Fat Content in Patients With DiabetesCompletedNCT01432405Phase 4Results posted
• Changes in Bone Turnover With Exposure to a GLP-1 Receptor AgonistTerminatedNCT01381926Phase 4Results posted
• Impact of Exenatide on Cardiovascular Exercise Performance in Type 2 DiabetesCompletedNCT01364584Not applicableResults posted
• A Safety Study to Assess the Effects of Therapeutic and Supratherapeutic Exenatide Concentrations on QT Interval in Healthy SubjectsCompletedNCT01297062Phase 1Results posted
• Use of Exenatide and Pramlintide to Decrease Post-prandial HyperglycemiaCompletedNCT01269047Phase 4Results posted
• New Onset Type 1 Diabetes: Role of ExenatideCompletedNCT01269034Phase 4Results posted
• A Pilot Clinical Trial of Exendin-4 in Alzheimer's DiseaseTerminatedNCT01255163Phase 2Results posted
• Exenatide in Extreme Pediatric ObesityCompletedNCT01237197Phase 2Results posted
• The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and PrediabetesCompletedNCT01181986Phase 4Results posted
• Exeantide in Type 2 Diabetes on InsulinCompletedNCT01154933Phase 2Results posted
• Effect of Different Interventions on Glycemic Control and β-cell Function in Newly Diagnosed Type 2 Diabetic PatientsCompletedNCT01147627Not applicableResults posted
• Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes MellitusCompletedNCT01144338Phase 3Results posted
• Impact of Exenatide on Sleep in Type 2 DiabetesCompletedNCT01136798Not applicableResults posted
• Continuous Glucose Monitoring Evaluation of Exenatide Twice Daily Versus Insulin GlargineCompletedNCT01089569Not applicableResults posted
• Effects of Exenatide on Hypothalamic ObesityCompletedNCT01061775Phase 1/2Results posted
• Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 DiabetesCompletedNCT01029886Phase 3Results posted
• Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver DiseaseCompletedNCT01006889Phase 4Results posted
• Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 DiabetesCompletedNCT01003184Phase 3Results posted
• A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 DiabetesCompletedNCT00960661Phase 3Results posted
• Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes MellitusCompletedNCT00935532Phase 3Results posted
• A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian SubjectsCompletedNCT00917267Phase 3Results posted
• A Study to Examine the Pharmacokinetics, Tolerability, Safety and Efficacy of Exenatide Once Weekly SuspensionCompletedNCT00894322Phase 1/2Results posted
• GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese ChildrenCompletedNCT00886626Phase 2Results posted
• Intravenous Exenatide (Byetta) During SurgeryCompletedNCT00882050Phase 1/2Results posted
• A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)CompletedNCT00877890Phase 3Results posted
• A Comparison of Adding Exenatide With Switching to Exenatide in Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus MetforminCompletedNCT00870194Phase 4Results posted
• The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese SubjectsCompletedNCT00856609Phase 3Results posted
• Evaluation of Exenatide in Patients With Diabetic NeuropathyCompletedNCT00855439Not applicableResults posted
• Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese AdultsCompletedNCT00845507Phase 4Results posted
• Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell FunctionCompletedNCT00845182Phase 4Results posted
• Evaluating the Use of Exenatide in People With Type 2 Diabetes and Diastolic Heart FailureTerminatedNCT00799435Phase 4Results posted
• A Study to Compare Methodologies for Assessing Glucose-Dependent Insulin Secretion (0000-104)(COMPLETED)CompletedNCT00782418Phase 1Results posted
• Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell MassCompletedNCT00775684Not applicableResults posted
• Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes MellitusCompletedNCT00765817Phase 3Results posted
• Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With MetforminCompletedNCT00753896Phase 3Results posted
• Intravenous Exenatide in Coronary Intensive Care Unit (ICU) PatientsCompletedNCT00736229Phase 4Results posted
• Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a ThiazolidinedioneCompletedNCT00729326Phase 4Results posted
• Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With MetforminTerminatedNCT00701935Phase 2Results posted
• Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)CompletedNCT00676338Phase 3Results posted
• How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 DiabeticsCompletedNCT00667732Phase 4Results posted
• Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 DiabetesCompletedNCT00658021Phase 3Results posted
• Role of Exenatide in NASH-a Pilot StudyCompletedNCT00650546Phase 2/3Results posted
• Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)CompletedNCT00641056Phase 3Results posted
• A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)CompletedNCT00637273Phase 3Results posted
• Bioenergetic Alterations After Exenatide AdministrationCompletedNCT00623545Phase 4Results posted
• Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and MetforminCompletedNCT00603239Phase 3Results posted
• Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s)CompletedNCT00577824Phase 3Results posted
• The Vascular Effects of Exenatide Versus Metformin in Patients With Pre-DiabetesCompletedNCT00546728Phase 4Results posted
• Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver DiseaseTerminatedNCT00529204Phase 2Results posted
• A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients With Type 2 DiabetesCompletedNCT00516074Phase 3Results posted
• An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients With Type 2 DiabetesCompletedNCT00516048Phase 3Results posted
• A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese PatientsCompletedNCT00500370Phase 2Results posted
• The Effect of Exenatide on Weight and Hunger in Obese, Healthy WomenCompletedNCT00456885Phase 4Results posted
• Role of Exenatide in Type 1 DiabetesCompletedNCT00456300Phase 2Results posted
• Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 DiabetesCompletedNCT00434954Phase 3Results posted
• Effect on Weight Loss of Exenatide Versus PlaceboCompletedNCT00375492Phase 3Results posted
• A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes PatientsCompletedNCT00360334Phase 3Results posted
• Exenatide Versus Glimepiride in Patients With Type 2 DiabetesCompletedNCT00359762Phase 3Results posted
• The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 DiabetesCompletedNCT00353834Phase 4Results posted
• Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)CompletedNCT00308139Phase 3Results posted
• An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes MellitusCompletedNCT00135330Phase 3Results posted
• Effects of Exenatide and Insulin Glargine in Subjects With Type 2 DiabetesCompletedNCT00097500Phase 3Results posted
• Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and MetforminCompletedNCT00082407Phase 3Results posted
• Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and MetforminCompletedNCT00082381Phase 3Results posted

← Exenatide overview